Douglas D. Leipold
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Peptidase Inhibition and Analysis, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index(2008)1,323 cited
- → The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates(2012)192 cited
- → Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry(2011)189 cited
- → Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity(2019)185 cited
- → Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice(2010)117 cited
- → Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering(2014)106 cited
- → Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)(2019)104 cited
- → A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer(2014)83 cited
- → Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers(2017)69 cited
- Endogenous natriuretic factors 7: biospecificity of a natriuretic gamma-tocopherol metabolite LLU-alpha.(1997)